ArticleBMC pediatrics2026
Single-center analysis of relapse risk factors and prognosis in 256 cases of ETV6::RUNX1-positive pediatric acute lymphoblastic leukemia.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAcute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and although ETV6::RUNX1–positive B-cell ALL generally carries a favorable prognosis, it has a notable risk of late relapse. This study aimed to identify key relapse-associated risk factors and evaluate their impact on survival outcomes in children with ETV6::RUNX1–positive ALL.
methodsWe performed a retrospective cohort study including 256 pediatric patients diagnosed with ETV6::RUNX1–positive ALL at the Children’s Hospital of Soochow University between May 2008 and August 2020. Clinical characteristics, treatment responses, and relapse patterns were assessed. Independent predictors of relapse were identified using multivariate logistic regression, and survival outcomes were analyzed using the Kaplan–Meier method.
resultsElevated initial white blood cell (WBC) count (≥ 50 × 10⁹/L), poor steroid response at day 7, and persistence of the ETV6::RUNX1 fusion transcript at the first post-therapy minimal residual disease assessment were significant independent predictors of relapse (P < 0.05). Among relapsed patients, early relapse (within 36 months of diagnosis) and lack of hematopoietic stem cell transplantation (HSCT) were associated with markedly inferior survival (5-year overall survival (OS): 17.6% vs. 55.6%, P = 0.006).
conclusionsThis study identifies three critical risk factors for relapse in ETV6::RUNX1–positive pediatric ALL and highlights the adverse prognostic impact of early relapse. Importantly, the persistent detection of ETV6::RUNX1 fusion transcript at initial minimal residual disease (MRD) evaluation emerged as a novel and independent biomarker for early risk stratification. These findings may guide refinement of individualized therapeutic strategies to improve long-term outcomes in this pediatric subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.